New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
08:57 EDTHEBHemispherx to present results to date of Ampligen/FluMist trial
Hemispherx Biopharma announced that the ASM Biodefense Meeting is scheduled for January 27-29 in Washington DC. The University of Alabama and Hemispherx's poster presentation is entitled "Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod (Ampligen), Given Intranasally Produced Cross-Reactive IgA Antibodies Against Pathogenic H5N1 Influenza HA" and will be provided in poster format by Dr. E. Turner Overton, an infectious disease expert at UAB, in the afternoon of January 29. Representatives of Hemispherx Biopharma and Prof. Overton, the principal researcher conducting the clinical trial at the University of Alabama at Birmingham, will describe the results to date of the Ampligen/FluMist intranasal influenza vaccine clinical trial and address questions during a media conference at the National Press Club in Washington, DC scheduled on Thursday, January 30.
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
16:13 EDTHEBHemispherx files $77.9M mixed securities shelf
Subscribe for More Information
08:36 EDTHEBHemispherx receives notice of intention to grant patent from EU
Hemispherx announced that it received formal notice on June 18, that the European Patent Office's Examining Division issued the formal notification of intention to grant the Hemispherx application titled "Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and Highly Specific Biologic Activity" by inventors Carter, et al. and assignee Hemispherx Biopharma, Inc. The patent claims a novel form of rugged dsRNA. Rugged dsRNA are nucleic acids with a unique composition and physical characteristic identified with high specificity of binding to Toll-Like Receptor 3, or TLR3, thereby conveying an important range of therapeutic opportunities. This form of dsRNA has increased bioactivity and binding affinity to the TLR 3 receptor because of its reduced tendency to form branched dsRNA that can inhibit receptor binding. Pharmaceutical formulations containing this nucleic acid as active ingredients, and methods of treatment with those formulations, are also described in the accepted application.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use